Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS-4642 + nab-paclitaxel + gemcitabine + nimotuzumab
- Development stage
- Phase 2
- Lead developer
- Hengrui Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
HRS-4642 + nab-paclitaxel + gemcitabine + nimotuzumab is an investigational combination therapy being evaluated for the treatment of borderline resectable pancreatic cancer with KRAS G12D mutations. The regimen includes HRS-4642, a selective, non-covalent, liposome-formulated small molecule inhibitor of the KRAS G12D mutant protein; nimotuzumab, a humanized monoclonal antibody targeting the epidermal growth factor receptor (EGFR); and the chemotherapy doublet AG (nab-paclitaxel and gemcitabine). HRS-4642 suppresses downstream MEK and ERK phosphorylation, while nimotuzumab blocks EGFR-mediated signaling. The combination aims to provide a multi-pronged attack on pancreatic ductal adenocarcinoma (PDAC) by targeting both the primary driver mutation and complementary growth pathways. This therapy is currently in Phase II clinical development led by Zhejiang University.
- Other names
- HRS-4642 + AG + nimotuzumabHRS-4642 + Nimotuzumab + Chemotherapy
02
Targets
DNAEGFR (Epidermal growth factor receptor)KRASG12D (Kirsten rat sarcoma viral oncogene homolog (KRAS) G12D mutant)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on HRS-4642 + nab-paclitaxel + gemcitabine + nimotuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS-4642 + nab-paclitaxel + gemcitabine + nimotuzumab.